We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Suitcase Laboratory Rapid Detects Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 15 Jun 2016
Print article
Image: The mobile suitcase laboratories. The mobile set up was built to host all reagents and equipment to perform the SpeedXtract (left suitcase). Another suitcase was used to perform the RPA assay (right suitcase) (Photo courtesy of University of Gottingen).
Image: The mobile suitcase laboratories. The mobile set up was built to host all reagents and equipment to perform the SpeedXtract (left suitcase). Another suitcase was used to perform the RPA assay (right suitcase) (Photo courtesy of University of Gottingen).
Leishmania donovani (LD) is a protozoan parasite transmitted to humans from sand flies, which causes Visceral Leishmaniasis (VL) and currently, the diagnosis is based on presence of the anti-LD antibodies and clinical symptoms.

Molecular diagnosis would require real-time polymerase chain reaction (qPCR), which is not easy to implement at field settings; however a recombinase polymerase amplification (RPA) assay has been developed and tested for the detection of LD.

Scientists at the Georg-August-University (Gottingen, Germany) and their colleagues tested a total of 48 archived DNA samples from VL patients, asymptomatic individuals and post-kala-azar dermal leishmaniasis (PKDL) patients were tested by both RPA and real-time PCR assays. To determine the specificity of the assay, the archived DNA samples including 35 endemic healthy controls, five non-endemic healthy controls and disease controls including six malaria cases and two tuberculosis cases were also investigated.

All VL, PKDL and asymptomatic cases were positive for LD DNA by realtime PCR, while controls (healthy and disease) were negative for rK39, direct antiglobulin test (DAT) and LD DNA by real-time PCR. Quantitative detection of Leishmania DNA was performed on a CFX96 real time detection system (Bio-Rad, Hercules CA, USA). Two mobile suitcase laboratories were constructed to have separate workspaces for nucleic acid extraction and detection in order to avoid any possible contamination. Blood samples were collected from seven patients hospitalized at the Surya Kanta Kala-azar Research Center, and nucleic acid was extracted from whole blood and RPA test was performed in the field.

The LD RPA assay detected equivalent to one LD genomic DNA. The assay was performed at constant temperature of 42 °C in 15 minutes. The RPA assay also detected other Leishmania species (L. major, L. aethiopica and L. infantum), but did not identify nucleic acid of other pathogens. Forty-eight samples from VL, asymptomatic and post-kala-azar dermal leishmaniasis subjects were detected positive and 48 LD-negative samples were negative by both LD RPA and real-time PCR assays, which indicates 100 % agreement. The suitcase laboratory was successfully operated at the local hospital by using a solar-powered battery. DNA extraction was performed by a novel magnetic bead based method (SpeedXtract, Qiagen, Hilden, Germany), in which a simple fast lysis protocol was applied. Moreover, all reagents were cold-chain independent.

The authors concluded that the use of a mobile suitcase laboratory is advantageous for rapid, sensitive and specific detection of LD using SpeedXtract and RPA assay, especially, at low resource settings such as Bangladesh and could contribute to VL control and elimination program. The study was published in the May 2016 issue of the journal Parasites &Vectors.

Related Links:
Georg-August-University
Bio-Rad
Qiagen
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Pathology

view channel
Image: A view of the brain with perturbation expression (Photo courtesy of Scripps Research)

Groundbreaking CRISPR Screen Technology Rapidly Determines Disease Mechanism from Tissues

Thanks to over a decade of advancements in human genetics, scientists have compiled extensive lists of genetic variations linked to a wide array of human diseases. However, understanding how a gene contributes... Read more